Keros Therapeutics, Inc.
KROSDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How KROS's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dose A KER-012 | Phase 2 | Pulmonary Arterial Hypertension | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Keros Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Keros Therapeutics, Inc.'s (KROS) pipeline across Phase 2. Its lead program is Dose A KER-012 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Keros Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Keros Therapeutics, Inc. (KROS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track KROS biotech catalysts?→
Add KROS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Keros Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.